Posted on 04/02/2010 in Pharmaceutical Company Financials Chugai's financial results for 2009 have been reported by Roche, which owns the majority stake in the organisation.
Last year, the pharmaceutical company witnessed an increase in sales, driven largely by demand for the H1N1 virus product Tamiflu, Roche stated.
This growth was also attributed to the popularity of Chugai's key cancer medicines and Actemra (tocilizumab) - the first humanised interleukin-6 receptor-inhibiting monoclonal antibody for the treatment of rheumatoid arthritis.
Additionally, Chugai recorded significant additional growth in the fourth quarter, following the approval of an expanded metastatic colorectal cancer indication.
Severin Schwan, chief executive of Roche, stated: "In a turbulent external environment, Roche performed extraordinarily well. Sales by both pharma and diagnostics grew twice as fast as their respective markets."
As of the end of December 2009, Roche owns 59.9 per cent of Chugai's outstanding shares, equating to 61.6 per cent of its voting rights.
In December, Chugai announced that management restructures have taken place as a result of its new ownership. Other news stories from 04/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
